Gradually , focus is growing within the United Kingdom regarding Tesamorelin as a promising therapy for lipodystrophy . While somewhat emerging , understanding of the advantages it offers – particularly in alleviating the symptoms of HIV-related lipodystrophy – is spreading . Clinicians are investigating its use , and patient demand is rising